The board of directors at Biogen Idec have elected to keep the company independent, after a two-month flirtation with selling out to a larger company. The company announced that it did not receive “any definitive offers” for an acquisition. Company shares dropped 28% in value after the announcement Refocused on its independent status, the company reiterated its year-end 2010 goals: Get 100,000 patients on Tysabri; Derive more than 40% of the its revenue from internat...